Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Non-Current Debt (2020 - 2025)

Oncology Institute (TOI) has disclosed Non-Current Debt for 5 consecutive years, with $76.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Debt fell 16.76% year-over-year to $76.2 million, compared with a TTM value of $76.2 million through Sep 2025, down 16.76%, and an annual FY2024 reading of $93.1 million, up 7.26% over the prior year.
  • Non-Current Debt was $76.2 million for Q3 2025 at Oncology Institute, up from $75.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $93.1 million in Q4 2024 and bottomed at $73.9 million in Q1 2025.
  • Average Non-Current Debt over 4 years is $83.5 million, with a median of $83.7 million recorded in 2023.
  • The sharpest move saw Non-Current Debt increased 7.82% in 2023, then decreased 16.76% in 2025.
  • Year by year, Non-Current Debt stood at $80.6 million in 2022, then grew by 7.7% to $86.8 million in 2023, then rose by 7.26% to $93.1 million in 2024, then dropped by 18.19% to $76.2 million in 2025.
  • Business Quant data shows Non-Current Debt for TOI at $76.2 million in Q3 2025, $75.0 million in Q2 2025, and $73.9 million in Q1 2025.